Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial

To investigate whether the degree of albuminuria reduction observed in the ALTITUDE trial is associated with renal and cardiovascular protection, and secondly, whether the reduction in albuminuria was too small to afford clinical benefit.

[1]  R. Gansevoort,et al.  Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. , 2014, Annals of internal medicine.

[2]  D. de Zeeuw,et al.  Microalbuminuria: target for renoprotective therapy PRO. , 2014, Kidney international.

[3]  H. Parving,et al.  Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors , 2014, Diabetes Care.

[4]  Paul Shekelle,et al.  Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease: A Clinical Practice Guideline From the American College of Physicians , 2013, Annals of Internal Medicine.

[5]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[6]  Paul Shekelle,et al.  Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians , 2013, Annals of Internal Medicine.

[7]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[8]  J. Chan,et al.  Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  S. Bangalore,et al.  Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials , 2013, BMJ.

[10]  H. Mischak,et al.  A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus , 2013, Diabetologia.

[11]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[12]  D. de Zeeuw,et al.  Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  T. Berl,et al.  Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. , 2011, European heart journal.

[14]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[15]  Mark Woodward,et al.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[16]  Stian Lydersen,et al.  Combining GFR and albuminuria to classify CKD improves prediction of ESRD. , 2009, Journal of the American Society of Nephrology : JASN.

[17]  S. Solomon,et al.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  D. de Zeeuw,et al.  Screening for albuminuria identifies individuals at increased renal risk. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  P. Colville-Nash,et al.  The role played by endocytosis in albumin-induced secretion of TGF-beta1 by proximal tubular epithelial cells. , 2007, American journal of physiology. Renal physiology.

[20]  B. Brenner,et al.  Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. , 2007, Journal of the American Society of Nephrology : JASN.

[21]  G. Bakris,et al.  The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.

[22]  E. Lewis,et al.  Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[24]  B. Brenner,et al.  Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.

[25]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[26]  K. Borch-Johnsen,et al.  Albuminuria reflects widespread vascular damage , 1989, Diabetologia.

[27]  M. Nieminen,et al.  Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study , 2003, Annals of Internal Medicine.

[28]  G. Remuzzi,et al.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.

[29]  Hans L Hillege,et al.  Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.

[30]  H. Parving,et al.  Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. , 2002, Diabetes.

[31]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[32]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[33]  H Birn,et al.  Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. , 2001, American journal of physiology. Renal physiology.

[34]  G. Remuzzi,et al.  Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. , 1998, Kidney international.

[35]  G. Remuzzi,et al.  Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.